Company will debut five-year results from GALE study showing meaningful impact of early and continuous treatment with SYFOVRE® (pegcetacoplan ...

Spot early warning signs of macular degeneration before vision loss begins. Know symptoms, risk factors, and when to see an ...

Learn about central retinal vein occlusion (CRVO), its causes, symptoms, diagnosis, and treatment options for vision loss.

Central vision loss from Age-related Macular Degeneration can begin subtly, faces blur, words distort, yet side vision ...

COLUMBUS – Prevent Blindness Ohio is declaring February as Age-related Macular Degeneration and Low Vision Month in an effort to provide education and various expert-approved resources to the public ...

Good morning, everyone, and thank you for joining us today. Earlier this morning, we issued a press release outlining the positive topline results from our SOL-1 Phase III clinical trial of AXPAXLI, ...

Ocular Therapeutix said it would release topline data from its Phase 3 superiority clinical trial of its Axpaxli treatment of wet age-related macular degeneration on Tuesday. Detailed data will be ...

In a statement issued on X today, the PTI emphasised that the government's lack of clarity regarding Imran's health had only intensified public unease. The party said it viewed the issue as more than ...

The live and archived webcast can also be accessed by visiting the Ocular Therapeutix website on the Events and Presentations section of the Investor Relations page. A replay of the webcast will be ...

The report states that unaided, Imran’s right eye had 6/24 partial vision in the right eye and 6/9 in the left.

New research suggests that weight-loss drugs can help prevent vision loss as patients age, but there's a major caveat.

Company advances Phase 3 AXPAXLI programs, with SOL-1 Week 52 data presentation set for February 2026 and SOL-R topline expected in Q1 2027.